Novartis Ag ADR (NVS)

Apr 2, 2025, 8:29 PM EDT - 8 hours ago

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Apr 2, 2025, 8:13 PM EDT - 9 hours ago

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Mar 31, 2025, 2:30 PM EDT - 2 days ago

Pharma tariffs the 'number one question' on investors' minds, Barclays says

AZN GSK NVO

Mar 31, 2025, 1:00 AM EDT - 3 days ago

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

Mar 28, 2025, 12:52 PM EDT - 5 days ago

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Mar 25, 2025, 2:15 AM EDT - 9 days ago

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Mar 20, 2025, 7:37 PM EDT - 13 days ago

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Mar 20, 2025, 7:11 PM EDT - 13 days ago

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

Mar 19, 2025, 8:45 AM EDT - 14 days ago

Novartis scraps use of diverse panels for hires in US

Mar 17, 2025, 1:46 AM EDT - 17 days ago

Novartis CEO says it is watching US reciprocal tariff policy 'very carefully'

Mar 14, 2025, 12:24 PM EDT - 19 days ago

Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032: Nantomics, Genentech, and Novartis are Pivotal in the Development of the $16.4 Billion Market

Mar 13, 2025, 8:03 AM EDT - 20 days ago

NFL signs Novartis as first pharmaceutical partner-source

Mar 13, 2025, 8:03 AM EDT - 20 days ago

Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy

Mar 7, 2025, 9:11 AM EST - 26 days ago

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

Mar 6, 2025, 7:00 AM EST - 27 days ago

10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil

CLX DEO FTS HRL JNJ KMB MO

Mar 6, 2025, 2:55 AM EST - 4 weeks ago

Novartis not panicking over potential US pharmaceutical tariffs, chairman says

Mar 5, 2025, 6:24 PM EST - 4 weeks ago

Final Trade: NVS, XLU, GM

GM XLU

Feb 28, 2025, 9:00 AM EST - 4 weeks ago

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Feb 28, 2025, 7:39 AM EST - 4 weeks ago

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

Feb 27, 2025, 10:09 AM EST - 4 weeks ago

Why Novartis Remains A 'Buy' After Beating Expectations Again

Feb 26, 2025, 4:39 AM EST - 5 weeks ago

Syngenta acquires genetic repository from Novartis to boost biologic crop protection

Feb 25, 2025, 1:55 PM EST - 5 weeks ago

Sandoz family foundation offers $3 billion worth of Novartis shares

Feb 20, 2025, 7:41 AM EST - 5 weeks ago

Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities

Feb 16, 2025, 12:02 AM EST - 6 weeks ago

Novartis: Strong Execution With A P/E Discount

Feb 14, 2025, 7:30 AM EST - 6 weeks ago

Novartis: Just What The Doctor Ordered

Feb 11, 2025, 1:41 AM EST - 7 weeks ago

Novartis agrees to acquire Anthos for up to $3.1 bln

Feb 11, 2025, 1:17 AM EST - 7 weeks ago

Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion

BX

Feb 11, 2025, 1:15 AM EST - 7 weeks ago

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Feb 3, 2025, 12:30 AM EST - 2 months ago

Novartis is considering further acquisitions to drive growth, CEO says

Jan 31, 2025, 12:20 PM EST - 2 months ago

Novartis AG (NVS) Q4 2024 Earnings Call Transcript

Jan 31, 2025, 5:07 AM EST - 2 months ago

Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales

Jan 31, 2025, 5:00 AM EST - 2 months ago

Novartis CEO says U.S. exit from global health programmes to affect millions

Jan 31, 2025, 1:14 AM EST - 2 months ago

Novartis beats consensus on Q4 earnings

Jan 31, 2025, 1:00 AM EST - 2 months ago

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

Jan 30, 2025, 2:39 PM EST - 2 months ago

AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?

ABBV

Jan 29, 2025, 9:00 AM EST - 2 months ago

10 Undervalued Dividend Growth Stocks: January 2025

BMY HRL HSY KMB PEP PFE SPY

Jan 16, 2025, 4:08 PM EST - 2 months ago

US appeals court lifts pause on generic version of Novartis' Entresto

Jan 16, 2025, 12:09 PM EST - 2 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

OTLK

Jan 15, 2025, 7:01 PM EST - 2 months ago

Novartis loses emergency bid to block Entresto generic in US

Jan 14, 2025, 2:57 PM EST - 2 months ago

Novartis AG (NVS) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)

Jan 14, 2025, 1:00 PM EST - 2 months ago

Novartis CEO: We need to get Europe to pay its fair share

Jan 14, 2025, 10:19 AM EST - 2 months ago

Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line

Jan 13, 2025, 6:10 PM EST - 2 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 13, 2025, 12:08 PM EST - 2 months ago

Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential

BIOA

Jan 13, 2025, 1:15 AM EST - 2 months ago

Novartis Entresto® US patent upheld by US Court of Appeals

Jan 10, 2025, 4:32 PM EST - 2 months ago

Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025

Jan 10, 2025, 10:25 AM EST - 2 months ago

AI, vaccine distrust, & the future of healthcare: Novartis CEO

Jan 9, 2025, 9:00 AM EST - 2 months ago

Light Horse Therapeutics Enters Into Strategic Collaboration With Novartis

Dec 30, 2024, 11:01 AM EST - 3 months ago

Novartis gene therapy helps children with rare muscle disorder in study

Dec 30, 2024, 12:45 AM EST - 3 months ago

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA